EFFICACY AND SAFETY OF COMBINATION TREATMENT OF TLR7 AGONIST TQA3334 AND ANTI-PD-L1 TQB2450 IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS: A PILOT RCT PHASE I I STUDY ( OCEAN cure05 STUDY)

被引：0

作者：

Wu, Ting ^{[1
]}

Wu, Di ^{[1
]}

Chen, Yuying ^{[1
]}

Huang, Da ^{[1
]}

Yuan, Zhize ^{[1
]}

Wang, Peng ^{[1
]}

Xu, Zhongnan ^{[2
]}

Wang, Shuna ^{[2
]}

Huo, Dandan ^{[2
]}

Yan, Weiming ^{[1
]}

Han, Meifang ^{[1
]}

Ning, Qin ^{[3
]}

Wang, Xiaojing ^{[4
,5
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept & Inst Infect Dis,Tongji Hosp, State Key Lab Diag & Treatment Severe Zoonot Infe, Wuhan 430030, Peoples R China

[2] Chia Tai Tianqing Pharmaceut Grp Co Ltd, Nanjing, Peoples R China

[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst & Dept Infect Dis, Wuhan, Peoples R China

[4] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China

[5] Huazhong Univ Sci & Technol, State Key Lab Diag & Treatment Severe Zoonost Inf, Wuhan, Peoples R China

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1467-C

引用

页码：S567 / S568

页数：2

共 6 条

[1] COMBINATION THERAPY WITH TLR7 AGONIST TQ-A3334 AND ANTI- PD-L1 TQ-B2450 ENHANCE HBSAG DECLINE IN VIRALLYSUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B: OCEANCURE05 STUDY
Wu, Di
Chen, Yuying
Huang, Da
Yuan, Zhize
Wu, Wenyu
Yuan, Wei
Peng, Wang
Xu, Zhongnan
Wang, Shuna
Huo, Dandan
Yuen, Man-Fung
Yan, Weiming
Han, Meifang
Ning, Qin
HEPATOLOGY, 2024, 80 : S230 - S231
[2] Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study
Gane, Edward
Dunbar, P. Rod
Brooks, Anna
Zhao, Yang
Tan, Susanna
Lau, Audrey
Yang, Jenny
Gaggar, Anuj
Subramanian, Mani
Kottilil, Shyamasundaran
Tang, Lydia
JOURNAL OF HEPATOLOGY, 2020, 73 : S52 - S52
[3] A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naive or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.
Gastman, Brian
Fling, Steven
Ansstas, George
Funchain, Pauline
Silk, Ann W.
Friedlander, Philip Adam
Curti, Brendan D.
Xing, Yan
Nguyen, Oanh
Christensen, Ann
Ferrando-Martinez, Sara
Lacroix, Andreanne
Lee, Byung Ha
Miller, David M.
Sosman, Jeffrey A.
Fan, Jean
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[4] Optimization of a Phase 2 Study Design in Chronic Hepatitis B (CHB) Patients Based on Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) from Phase 1 Studies Using Two Prodrugs of a Toll-like Receptor 7 (TLR7) Agonist
Grippo, Joseph
Folitar, Ilia
de Rooij, Jeroen van de Wetering
Passe, Sharon
Blue, David R.
Rodriguez, Ignacio
Fettner, Scott H.
Calleja, Elizabeth
HEPATOLOGY, 2016, 64 : 924A - 924A
[5] Safety, efficacy, and pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study
Lim, Young-Suk
Hui, Aric J.
Jang, Jeong-Won
Tak, Won-Young
Ahn, Sang Hoon
Jang, Byoung Kuk
Tsang, Tak Yin Owen
Kim, Won
Yang, Jenny
Chen, Diana
McDonald, Circe
Zhang, Liao
Gaggar, Anuj
Gao, Bing
Byun, Kwan Soo
Lee, Kwan Sik
Yim, Hyung Joon
Chan, Henry L. Y.
JOURNAL OF HEPATOLOGY, 2021, 75 : S757 - S757
[6] Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.
Melisi, Davide
Guba, Susan C.
Karasarides, Maria
Andre, Valerie
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)

← 1 →